LEXINGTON, Mass., April 14, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Curis scientists and its collaborator, Aurigene Discovery Technologies Limited, will present data from two programs at the Annual Meeting of American Association of Cancer Research (AACR) to be held April 18 – 22, 2015 in Philadelphia.
Curis researchers will present data for its proprietary targeted cancer drug candidate, CUDC-427, an oral antagonist of inhibitor of apoptosis or IAP proteins. Curis' collaborator, Aurigene will present data from their interleukin-1 receptor association kinase-4, or IRAK-4, inhibitor program.
Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.
| Poster Presentations | |
| CUDC-427 program: | |
| Date/Time: | Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM |
| Session Title: | Predictive Biomarkers 2 |
| Session Category: | Clinical Research |
| Presentation Title: | Predictive biomarker signatures for IAP inhibitor CUDC-427 |
| Abstract Number: | 4324 |
| Date/Time: | Wednesday, Apr 22, 2015, 8:00 AM - 12:00 PM |
| Session Title: | Role of the Microenvironment and Tumor Metabolism in Therapeutic Response |
| Session Category: | Experimental and Molecular Therapeutics |
| Presentation Title: | IAP inhibitor CUDC-427 induces tumor regression or stasis in preclinical models of B cell lymphoma |
| Abstract Number: | 5502 |
| IRAK-4 program: | |
| Date/Time: | Tuesday, Apr 21, 2015, 8:00 AM - 12:00 PM |
| Session Title: | Drug Discovery: Kinases, Nuclear Hormone Receptors, and Novel Targets |
| Session Category: | Chemistry |
| Presentation Title: | Novel IRAK-4 inhibitors exhibit highly potent anti-proliferative activity in DLBCL cell lines with activating MYD88 L265P mutation |
| Abstract Number: | 3646 |
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual HDAC and PI3K inhibitor, CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-305, an oral HSP90 inhibitor. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis expects to exercise options to exclusively license oral small molecule antagonists of PD-L1 and IRAK4 and file IND application for both molecules in 2015. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
About Aurigene
Aurigene is a specialized, discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene's Programmed Death pathway program is the first of several immune checkpoint programs that are at different stages of discovery and preclinical development. Aurigene has partnered with several large- and mid-pharma companies in the United States and Europe and has delivered multiple clinical compounds through these partnerships. With over 500 scientists, Aurigene has collaborated with 6 of the top 10 pharma companies. Aurigene is an independent, wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. (NYSE:RDY). For more information, please visit Aurigene's website at http://aurigene.com/.
For More Information:
Mani Mohindru, Ph.D.
Vice President, Corporate Strategy and Investor Relations
Curis, Inc.
617-503-6605
mmohindru@curis.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com